GSM7401443: SK-OV-3 cells, doxorubicin 300 nM + IN10018 3 μM treatment, 24 hours, rep2; Homo sapiens; RNA-Seq
Transcriptome profiling was performed to determine the mechanism of the observed clinical antitumor effects. In brief, the SK-OV-3 cells were treated with DMSO, 300 nM doxorubicin, 3 μM IN10018, and a combination of IN10018 and doxorubicin for 24 hours. The total mRNA was extracted for the RNA sequencing. RNA was harvested using RNA iso plus reagent (Takara). 1.0 ug of total RNA was used for the construction of sequencing libraries. RNA libraries for RNA-seq were prepared using NEBNext Ultra Directional RNA Library Prep kit for Illumina (New England Biolabs) following manufacturer's protocols.